In contrast to broadly expressed classical class I antigens of the major histocompatibility complex, structurally closely related TL antigens are expressed in a highly restricted fashion. Unlike classical class I antigens, TL antigens are not known to be targets of cytotoxic T cells or to mediate graft rejection. Whereas classical class I antigens function as antigen-presenting molecules to T cell receptors (TCR), the role of TL is yet to be defined. To elucidate the function of TL, we have derived transgenic mice expressing TL in most tissues including skin by introducing a "['L gene, T3 b of C57BL/6 mouse origin, driven by the H-2K b promoter. By grafting the skin of transgenic mice, we demonstrate that TL can serve as a transplantation antigen and mediate a TCR-ot/B + CD8 + cytotoxic T cell response. This T cell recognition of TL does not require antigen presentation by H-2 molecules. Furthermore, we show that C57BL/6 F1 mice develop CD8 § T cells that are cytotoxic for C57BL/6 TL + leukemia cells, providing further support for the concept that aberrantly expressed nonmutated proteins such as TL can be recognized as tumor antigens.
H umans and mice have over a dozen class I genes belonging to the MHC, the majority of which are "nonclassical" class I or class "Ib" genes (1) (2) (3) . In contrast to well studied "classical" class I or class "Ia" genes, the function of nonclassical class I genes remains largely unexamined. Certain nonclassical class I genes have expression patterns similar to those of classical class I genes and have been shown to mediate graft rejection and CTL response, and even to present peptides to the TCR (4-7). It has been reported recently that Hmt, a member of nonclassical class I antigens, is specialized to present N-formyl peptides to TCR (8, 9) and that Qa-2, another nonclassical class I antigen, binds to a limited set of peptides (10) . Some nonclassical MHC products have been speculated to present antigens to TCR-3'/8 (11) (12) (13) . However, not all nonclassical class I genes are antigen-presenting molecules for TCR, e.g., a class I gene expressed in rat intestine functions as an Fc receptor of IgG (14) .
TL represents one of the earliest and best defined cell surface antigenic systems coded for by nonclassical class I genes in the MHC locus (15, 16) . Principal characteristics of TL include expression restricted to thymocytes during T cell development in TL + mice (e.g., A-strain and BALB/c), no expression in thymocytes of certain strains (TL-mice, e.g., C57BL/6 [B6] 1 and C3H/He [C3H]), anomalous TL expression in T cell lymphomas arising in TL-mice, and a phenomenon termed antigenic modulation in which TL expression is downregulated in the presence of TL antibody (15) (16) (17) . Until recently, TL expression was thought to be restricted to normal and leukemic cells of T cell derivation, but two reports (18, 19) have now shown that TL is expressed in the intestinal epithelium, raising the possibility that TL may be a presenting element for y/8 T cells in the gut. In addition, our recent studies with TL transgenic mice showing arrest of T cell maturation suggest that TL plays a critical role in T cell development in the thymus (20, 21) .
TL antigens are glycoproteins with a molecular mass of approximately 45,000 that are associated with/~2-microglobulin (22, 23) . Molecular analysis revealed that TL genes have an exon/intron structure very similar to that of classical class I genes and share ~70% identity in the nucleotide sequence of the coding region and in the putative amino acid sequence (16, (24) (25) (26) (27) . Despite these structural similarities, there has been no evidence that TL antigens are histocompatibility antigens or that they can induce a CTL response (15, 28) , and this has led to the speculation that TL antigens have a function distinct from that of classical class I antigens. To explore the role of nonclassical class I antigens with limited tissue distribution, such as TL, we have taken advantage of the newly derived transgenic TL strains to ask whether TL antigens can serve as transplantation rejection antigens and elicit a TLrestricted CTL response.
labeled TL-specific probe, pTL1 (24) . The same membrane was rehybridized with 3-actin cDNA (36) to standardize the amount of transcripts. The intensity of bands was measured by densitometric analysis with a Fujix Bio-imaging Analysis System (Fuji Photo Film Co., Tokyo, Japan).
Immunohistochemistry. 5-#m frozen sections of the skin were air dried, fixed with cold acetone, and stained with rat mAb by the avidin-biotinylated horseradish peroxidase complex (ABC) method (Vectastain; Vector Laboratories Inc., Burlingame, CA).
Skin Graft. Female C3H, (B6 x C3H)F1 and transgenic mice (6-10-wk-old) were used as recipients or donors. Full-thickness sections of skin (1-cm disk) were obtained from the abdomen of donors and were grafted to the back of recipients. Plaster casts were removed on day 10 and grafts were observed daily for at least 100 d.
CTL Assay. 4-8 wk after the rejection of grafted skin, spleen cells (3 x 107) from the mice were restimulated in vitro by culturing with 2 x 107 Tg.Con.3-1 spleen cells pretreated with 50 #g/ml mitomycin C (Wako Pure Chemical Industries, Osaka, Japan). After 6 d in culture, effector cells were harvested to test for cell-mediated cytotoxicity. Target cells were blast cells or tumor cells. To generate blast cells, spleen cells were cultured for 3 d in the presence of Con A (Boehringer Mannheim GmbH, Mannheim, Germany) at a concentration of 5 #g/ml. Labeled target cells were prepared by incubating 107 blast or tumor cells with 3.7 MBq of Na2SlCrO4 (New England Nuclear, Boston, MA) in 0.2 ml of medium for 45 min, followed by washing three times with RPMI-1640. Target cells (2 x 104) were incubated with various numbers of effector cells. After incubation for 3 h, the supernatants were harvested using Supernatant Collection System (Skatron Inc., Lier, Norway) for measurement of 51Cr release. The percent specific lysis was calculated by the following equation: 100
where a is the radioactivity in the supernatant of target cells mixed with effector cells, b is the radioactivity in the supernatant of target cells incubated without effector cells, and c is the radioactivity in the supernatant after complete lysis of target cells with 2% of Triton X-100.
Blocking Test of CTL Activity by Antibody. Serially diluted antibodies were added to the mixture of effector cells and labeled target cells in CTL assays to characterize the effector cells and target molecules. The amount of transcripts in the skin of Tg.Con.3-1 and Tg.-Con.3-2 is equivalent to that in the lymph nodes of the corresponding strains and is extremely large, as much as 57 (Tg.Con.3-1) and 18 times (Tg.Con. that in the B6 TL + leukemia ERLD, and 18 (Tg.Con.3-1) and 6 times (Tg.Con.3-2) that in TL + normal thymus of Tla 9 mice (Fig. 2) . The major transcripts in the skin are 2.1 kb, which is the expected size when the chimeric gene is tran- scribed from the initiation site of H-2I( ~ through the 3' untranslated region of T3 b (37) . Sequence analysis of cDNA generated from the mRNA of transgenic skin indicated that transcripts of the chimeric gene are properly processed and no unique junction peptides are created as a result of construction of the chimeric gene (data not shown). Thus, it is most likely that the cell surface product of the chimeric gene is T3b-TL antigen and that the entire leader peptide of H-2K b origin is removed from the mature protein. Immunostaining of transgenic mouse skin with TL antibody showed that TL antigen is expressed in epidermal keratinocytes, hair follicles, and dermal cells (Fig. 3) .
Results

TL Expression in the
T L Antigen as a Transplantation Antigen. To test whether TL expressed in the skin can serve as a transplantation rejec- tion antigen, skin graft experiments were carried out in various combinations of transgenic and inbred mice (Table 1) . Skin grafts from Tg.Con.3-1 and Tg.Con.3-2 were rejected efficiently by recipient C3H mice. Skin grafts of the higher expressor, Tg.Con.3-1, were rejected faster than Tg.Con.3-2 grafts. Both transgenic strains accepted C3H skin, indicating no genetic drift between C3H and transgenic mice. Reciprocal grafts between the two transgenic strains were also compatible, thus removing the possibility that genes at chromosomal integration sites of the transgene are expressed in such a way Figure 3 . TL antigen in the skin of transgenic mice detected by immunohistology with the ABC method. The panels are Tg.Con.3-1 skin stained with rat mAb to TL (HD168); C3H skin with HD168, and C3H skin with rat mAb to H-2 (HD464). The expression pattern of TL in the skin of transgenic mice is identical to that of H-2 in C3H mice. skin grafts. CTL from these mice lysed TL § blast target cells generated by Con A stimulation, but failed to lyse TLblast cells (Fig. 4) . The CTL response was characterized by blocking tests with various antibodies (Fig. 5) , and also by flow cytometric analysis (data not shown). The results demonstrated that the CTL are CD4-/CD8 +/CD3 +/TCRc~I$ + / TCR3"6-, having the conventional CTL phenotype. The 781 Morita et al.
target molecule for TL-specific CTL was determined by blocking tests with various TL and H-2 antibodies. As shown in Fig. 6 , none of the H-2 antibodies blocked cytotoxicity, whereas TL antibodies having serological specificities for different TL determinants blocked cytotoxicity. Thus, the recognition of TL by CTL does not require antigen presentation by H-2 molecules. This lack of H-2 involvement is further supported by the finding that TL-reactive CTL generated in C3H mice lyse TL + lymphomas of various H-2 haplotypes but not TL-lymphomas (Fig. 7) .
Recognition of T3b-TL Antigen by B6F~
Mice, A single gene, T3 b, encodes TL in B6 mice (24) . The anomalous expression of TL in B6 lymphomas results from the transcriptional activation of T3 b, which is silent in normal B6 T cells (15, 24) . T3 b isolated from a TL + B6 lymphoma, ERLD, contains no mutations in its coding region and is identical to T3 b derived from normal B6 mice. TL antigens can elicit a high level of humoral immunity in TL-mice (38) , and for this reason, TL antigens anomalously expressed in T cell lymphomas of TL-mice have long been regarded as tumorspecific antigens (15) . However, this idea has been called into question with recent reports demonstrating TL expression in the intestinal epithelium of TL-strains, such as B6 mice, as well as in TL + strains (18, 19) . We have confirmed this observation and have shown that TL transcripts and TL products are present in the intestine of B6, C3H, AKR, BALB/c, (B6 x C3H)F,, and also TL transgenic Tg.Tla~-3-1 and Tg.Tlaa-3-2 mice (Obata, Y., T. Takahashi, E. Stockert, and L.J. Old, unpublished observations). To test the significance of these findings in relation to TL as a tumor antigen, the ability of TL-mice to mount a CTL response to the T3 b-TL product was examined by grafting the skin of transgenic mice on (B6 x C3H)Ft mice (Table 1) . Tg.Con.3-1 grafts were rejected by F1 recipients, whereas Tg.Con.3-2 grafts were not, although a crisis was observed in half of the transplants. To resolve this difference, (B6 x C3H)F, mice were simultaneously engrafted with both Tg.Con.3-1 and Tg.Con.3-2 skins. In this experiment, not only Tg.Con.3-1 but also Tg.Con.3-2 grafts were rejected. The results clearly show that TL-mice can recognize the T3b-TL antigen as a transplantation antigen. The results also indicate that TL expression No CTL activity is detected Effector to target cell ratio against TL -blast cells of Tg.H2Kb-1 or C3H (data not shown). The CTL are TCR-ot/B + CD8 + cells and are independent of H-2 restriction, similar to TL-specific CTL induced in C3H mice.
above a certain level is required to mediate graft rejection. Mice grafted with Tg.Con.3-1 or Tg.Con.3-2 skin produced TL antibody (data not shown), and antigenic modulation, e.g., the reversible downregulation of TL antigen induced by TL antibody (17) , may be the reason for the failure to reject grafts expressing lower levels of TL. CTL induced in (B6 x C3H)FI mice lysed not only TL § Con A blast cells but also TL + B6 lymphomas, including ERLD (Fig. 8) . No obvious histological abnormalities were observed in the intestine of immunized (B6 x C3H)F1 mice having TLspecific CTL. Thus, despite TL expression in intestinal epithelial cells, TL can be recognized as a transplantation rejection antigen in TL-mice, supporting the original notion that anomalously expressed TL behaves like a tumor-specific antigen in TL-mice. It was further established that once CTL are induced by immunization with a critical level of TL, even cells expressing smaller amounts of TL become targets for rejection.
Discussion
In this study, we show that TL can mediate a transplantation rejection response and elicit CTL that are TL specific and independent of antigen presentation by classical class I molecules. With regard to classical class I antigens, the mechanisms for allo-recognition have been extensively studied and two distinct models have been proposed: (a) CTL recognizes allele-specific polymorphic residues on the MHC molecules (39-41); and (b) CTL recognizes endogenous peptides presented by altogeneic MHC molecules (42) (43) (44) (45) . Similar models can be proposed for TL recognition: CTL may recognize TL antigen per se or TL + X, where X are peptides presented by TL molecules. Structural comparisons reveal that TL molecules can form peptide-binding clefts similar to classical class I antigens (46, 47) , and that these peptide-binding regions of TL, in contrast to classical class I antigens, have a very limited polymorphism, suggesting that TL binds only a limited repertoire of peptides. In this respect, Qa-2 has been reported to bind to a relatively small number of peptides as compared with H-2 (10). It will be important to isolate and identify the peptides eluted from TL molecules expressed on normal and leukemic TL + cells in order to elucidate the function of TL as an antigen-presenting molecule and to determine the target specificity of TL-specific CTL.
Since the initial description of TL 30 years ago (38), numerous attempts have been made to induce CTL against TL, but without success. Our ability to generate TL-specific CTL in this study is most likely due to immunization with skin grafts from transgenic mice expressing abnormally high levels of TL. In support of this idea, we have found that immunization with spleen cells from TL transgenic mice was far less efficient in CTL induction than immunization with skin grafts. Even after hyperimmunization with spleen cells from Tg.Con.3-1, (B6 x C3H)F1 mice generated CTL with only low CTL activity ('~10% specific lysis of Tg.Con.3-1 blast cells). Because the skin consists of several different cell types with antigen-presenting characteristics, i.e., keratinocytes, Langerhans cells, and others, we are now attempting to identify which cells are responsible for TL-specific CTL induction and what costimulatory molecules may be involved.
The fact that TL can elicit humoral and cellular recognition in TL-mice such as B6 and B6Ft, despite TL expression in intestinal epithelium, indicates that intestinal TL expression does not induce a state of systemic tolerance to TL. This is in contrast to TL + mice, where TL expression in the thymus induces a tolerant state that precludes formation of TL-specific antibodies or CTL. No obvious histological abnormalities have been observed in the intestine of immunized (B6 x C3H)F1 mice with TL-specific CTL, suggesting (among other possibilities) that intestinal TL is inaccessible to cellular immune attack or that intestinal TL expression is downregulated via TL antibody-mediated antigenic modulation. In a typical graft-vs.-host reaction involving classical class I MHC mismatches, mice generally suffer from diarrhea and the small intestine shows pathological findings such as crypt hyperplasia (48, 49) , reduction in the ratio of villus length to crypt length (48, 50) , and lymphocytic infiltration of the epithelium (49) .
Antigenic modulation has long been considered the reason that TL-mice with high levels of TL antibody are not resistant to challenge with syngeneic TL + leukemias (17) . However, we have recently observed that (B6 x C3H)Ft mice immunized with Tg.Con.3-1 skin showed heightened resistance to a challenge with a TL + leukemia, but not a TL-leukemia. The poor capacity of lymphoid cells (in contrast to skin cells) to generate TL-specific CTL may account for the failure of past efforts to induce tumor resistance in TL-immunized mice. Understanding why skin-presented antigens are so effective in eliciting CTL to self-antigens like TL may provide new approaches to generating antitumor immunity.
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